Literature DB >> 22988240

β-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects.

Brian Hitt1, Sean M Riordan, Lokesh Kukreja, William A Eimer, Tharinda W Rajapaksha, Robert Vassar.   

Abstract

BACE1 is the β-secretase enzyme that initiates production of the β-amyloid peptide involved in Alzheimer disease. However, little is known about the functions of BACE1. BACE1-deficient mice exhibit mild but complex neurological phenotypes suggesting therapeutic BACE1 inhibition may not be completely free of mechanism-based side effects. Recently, we have reported that BACE1 null mice have axon guidance defects in olfactory sensory neuron projections to glomeruli in the olfactory bulb. Here, we show that BACE1 deficiency also causes an axon guidance defect in the hippocampus, a shortened and disorganized infrapyramidal bundle of the mossy fiber projection from the dentate gyrus to CA3. Although we observed that a classical axon guidance molecule, EphA4, was cleaved by BACE1 when co-expressed with BACE1 in HEK293 cells, we could find no evidence of BACE1 processing of EphA4 in the brain. Remarkably, we discovered that the axon guidance defects of BACE1(-/-) mice were strikingly similar to those of mice deficient in a recently identified BACE1 substrate, the neural cell adhesion molecule close homolog of L1 (CHL1) that is involved in neurite outgrowth. CHL1 undergoes BACE1-dependent processing in BACE1(+/+), but not BACE1(-/-), hippocampus, and olfactory bulb, indicating that CHL1 is a BACE1 substrate in vivo. Finally, BACE1 and CHL1 co-localize in the terminals of hippocampal mossy fibers, olfactory sensory neuron axons, and growth cones of primary hippocampal neurons. We conclude that BACE1(-/-) axon guidance defects are likely the result of abrogated BACE1 processing of CHL1 and that BACE1 deficiency produces a CHL1 loss-of-function phenotype. Our results imply the possibility that axon mis-targeting may occur in adult neurogenic and/or regenerating neurons as a result of chronic BACE1 inhibition and add a note of caution to BACE1 inhibitor development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22988240      PMCID: PMC3493884          DOI: 10.1074/jbc.M112.415505

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo.

Authors:  Lujia Zhou; Soraia Barão; Mathias Laga; Katrijn Bockstael; Marianne Borgers; Harry Gijsen; Wim Annaert; Diederik Moechars; Marc Mercken; Kris Gevaert; Kris Gevaer; Bart De Strooper
Journal:  J Biol Chem       Date:  2012-06-12       Impact factor: 5.157

2.  Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons.

Authors:  Peer-Hendrik Kuhn; Katarzyna Koroniak; Sebastian Hogl; Alessio Colombo; Ulrike Zeitschel; Michael Willem; Christiane Volbracht; Ute Schepers; Axel Imhof; Albrecht Hoffmeister; Christian Haass; Steffen Roßner; Stefan Bräse; Stefan F Lichtenthaler
Journal:  EMBO J       Date:  2012-06-22       Impact factor: 11.598

3.  Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.

Authors:  R Yan; M J Bienkowski; M E Shuck; H Miao; M C Tory; A M Pauley; J R Brashier; N C Stratman; W R Mathews; A E Buhl; D B Carter; A G Tomasselli; L A Parodi; R L Heinrikson; M E Gurney
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

4.  Purification and cloning of amyloid precursor protein beta-secretase from human brain.

Authors:  S Sinha; J P Anderson; R Barbour; G S Basi; R Caccavello; D Davis; M Doan; H F Dovey; N Frigon; J Hong; K Jacobson-Croak; N Jewett; P Keim; J Knops; I Lieberburg; M Power; H Tan; G Tatsuno; J Tung; D Schenk; P Seubert; S M Suomensaari; S Wang; D Walker; J Zhao; L McConlogue; V John
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

Review 5.  Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective.

Authors:  Rudolph E Tanzi; Lars Bertram
Journal:  Cell       Date:  2005-02-25       Impact factor: 41.582

6.  EphA4 signaling in juveniles establishes topographic specificity of structural plasticity in the hippocampus.

Authors:  Ivan Galimberti; Ewa Bednarek; Flavio Donato; Pico Caroni
Journal:  Neuron       Date:  2010-03-11       Impact factor: 17.173

7.  A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.

Authors:  Thorlakur Jonsson; Jasvinder K Atwal; Stacy Steinberg; Jon Snaedal; Palmi V Jonsson; Sigurbjorn Bjornsson; Hreinn Stefansson; Patrick Sulem; Daniel Gudbjartsson; Janice Maloney; Kwame Hoyte; Amy Gustafson; Yichin Liu; Yanmei Lu; Tushar Bhangale; Robert R Graham; Johanna Huttenlocher; Gyda Bjornsdottir; Ole A Andreassen; Erik G Jönsson; Aarno Palotie; Timothy W Behrens; Olafur T Magnusson; Augustine Kong; Unnur Thorsteinsdottir; Ryan J Watts; Kari Stefansson
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962

8.  BACE1 deficiency causes altered neuronal activity and neurodegeneration.

Authors:  Xiangyou Hu; Xiangdong Zhou; Wanxia He; Jun Yang; Wencheng Xiong; Philip Wong; Christopher G Wilson; Riqiang Yan
Journal:  J Neurosci       Date:  2010-06-30       Impact factor: 6.167

9.  Abnormalities in neuronal process extension, hippocampal development, and the ventricular system of L1 knockout mice.

Authors:  G P Demyanenko; A Y Tsai; P F Maness
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

10.  ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice.

Authors:  Victor H Guaiquil; Steven Swendeman; Wenhui Zhou; Patricio Guaiquil; Gisela Weskamp; Jörg W Bartsch; Carl P Blobel
Journal:  J Mol Med (Berl)       Date:  2010-01-30       Impact factor: 4.599

View more
  64 in total

1.  miR-186 is decreased in aged brain and suppresses BACE1 expression.

Authors:  Jaekwang Kim; Hyejin Yoon; Dah-Eun Chung; Jennifer L Brown; Krystal C Belmonte; Jungsu Kim
Journal:  J Neurochem       Date:  2016-03-30       Impact factor: 5.372

2.  Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice.

Authors:  Takashi Mori; Naoki Koyama; Tatsuya Segawa; Masahiro Maeda; Nobuhiro Maruyama; Noriaki Kinoshita; Huayan Hou; Jun Tan; Terrence Town
Journal:  J Biol Chem       Date:  2014-08-25       Impact factor: 5.157

3.  Curcumin Ameliorates Memory Decline via Inhibiting BACE1 Expression and β-Amyloid Pathology in 5×FAD Transgenic Mice.

Authors:  Kunmu Zheng; Xiaoman Dai; Nai'an Xiao; Xilin Wu; Zhen Wei; Wenting Fang; Yuangui Zhu; Jing Zhang; Xiaochun Chen
Journal:  Mol Neurobiol       Date:  2016-02-24       Impact factor: 5.590

Review 4.  Disturbed calcium signaling in spinocerebellar ataxias and Alzheimer's disease.

Authors:  Polina Egorova; Elena Popugaeva; Ilya Bezprozvanny
Journal:  Semin Cell Dev Biol       Date:  2015-04-04       Impact factor: 7.727

5.  Reduction of the expression of the late-onset Alzheimer's disease (AD) risk-factor BIN1 does not affect amyloid pathology in an AD mouse model.

Authors:  Robert J Andrew; Pierre De Rossi; Phuong Nguyen; Haley R Kowalski; Aleksandra J Recupero; Thomas Guerbette; Sofia V Krause; Richard C Rice; Lisa Laury-Kleintop; Steven L Wagner; Gopal Thinakaran
Journal:  J Biol Chem       Date:  2019-01-28       Impact factor: 5.157

Review 6.  Proteolytic ectodomain shedding of membrane proteins in mammals-hardware, concepts, and recent developments.

Authors:  Stefan F Lichtenthaler; Marius K Lemberg; Regina Fluhrer
Journal:  EMBO J       Date:  2018-07-05       Impact factor: 11.598

Review 7.  A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.

Authors:  Brati Das; Riqiang Yan
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

Review 8.  Developing therapeutic antibodies for neurodegenerative disease.

Authors:  Y Joy Yu; Ryan J Watts
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

9.  Between new genetic discoveries and large randomized trials--neurological research in the era of systems medicine.

Authors:  Thomas Misgeld; Stefan F Lichtenthaler; Martin Dichgans
Journal:  EMBO Rep       Date:  2013-05-14       Impact factor: 8.807

Review 10.  Targeting the β secretase BACE1 for Alzheimer's disease therapy.

Authors:  Riqiang Yan; Robert Vassar
Journal:  Lancet Neurol       Date:  2014-02-17       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.